Detection and Characterization of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates in Canada: Results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 945-959

  Adam, Heather J ^a   Louie, Lisa ^b   Watt, Christine ^b   Gravel, Denise ^c   Bryce, Elizabeth ^d   Loeb, Mark ^e,t   Matlow, Anne ^a,f   McGeer, Allison ^a,g   Mulvey, Michael R ^h   Simor, Andrew E ^a,b   Boyd, David ^h   Conly, John ⁱ   Embil, John ^j   Embree, Joanne ^j   Forgie, Sarah ^k   Frenette, Charles ^l   Gardam, Michael ^m   Henderson, Elizabeth ⁿ   Hutchinson, James ^o   John, Michael ^p   Johnston, Lynn ^q   Kibsey, Pamela ^r   Langley, Joanne ^s   Lemieux, Camille ^m   Michaud, Sophie ^u   Miller, Mark ^v   Moore, Dorothy ^w   Ofner Agostini, Marianne ^c   Pelude, Linda ^c   Roth, Virginia ^x   Simor, Andrew ^b   Suh, Kathryn ^x   Taylor, Geoffrey ^y   Thomas, Eva ^z   Thompson, William ^aa   Turgeon, Nathalie ^ab   Vayalumkal, Joseph ^ac   Vearncombe, Mary ^y   Weiss, Karl ^ad   Wong, Alice ^ae   Zoutman, Dick ^af   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g MOUNT SINAI HOSPITAL   (Canada)

^h PUBLIC HEALTH AGENCY OF CANADA   (Canada)

ⁱ FOOTHILLS HOSPITAL   (Canada)

^j HEALTH SCIENCES CENTRE   (Canada)

^k STOLLERY CHILDREN S HOSPITAL   (Canada)

^l MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^m UNIVERSITY HEALTH NETWORK   (Canada)

ⁿ Peter Lougheed Centre   (Canada)

^o Health Sciences Centre St John's   (Canada)

^p LONDON HEALTH SCIENCES CENTRE   (Canada)

^q QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^r VICTORIA GENERAL HOSPITAL   (Canada)

^s IWK HEALTH CENTRE   (Canada)

^t HAMILTON HEALTH SCIENCES   (Canada)

^u CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^v MCGILL UNIVERSITY   (Canada)

^w MONTREAL CHILDREN S HOSPITAL   (Canada)

^x UNIVERSITY OF OTTAWA   (Canada)

^y UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^z CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^aa Hôtel Dieu de Québec du CHUQ ^*  (Canada)

^ab LAVAL UNIVERSITY   (Canada)

^ac ALBERTA CHILDREN'S HOSPITAL   (Canada)

^ad MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^ae ROYAL UNIVERSITY HOSPITAL   (Canada)

^af KINGSTON GENERAL HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; CANADA; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DETERMINATION; FEMALE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; POPULATION STRUCTURE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 75749124215     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01316-09     Document Type: Article

References (32)

1. Alós, J. I., A. Garcia-Cañas, P. Garcia-Hierro, and F. Rodriguez-Salvanés. 2008. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J. Antimicrob. Chemother. 62:773-775.
2. Ariza, J., M. Pujol, J. Cabo, C. Peña, N. Fernández, J. Liñares, J. Ayats, and F. Gudiol. 1999. Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588.
3. Charles, P. G. P., P. B. Ward, P. D. R. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451.
4. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing. nineteenth informational supplement. M100-S19. Clinical Laboratory Standards Institute, Wayne, PA.
5. Garnier, F., D. Chainier, T. Walsh, A. Karlsson, A. Bolmström, C. Grelaud, M. Mounier, F. Denis, and M.-C. Ploy. 2006. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J. Antimicrob. Chemother. 57:146-149.
6. Hiramatsu, K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155.
7. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
8. Horan, T. C., M. Andrus, and M. A. Dudeck. 2008. CDC/NHSN surveillance definition of healthcare-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control 36:309-332.
9. Horne, K. C., B. P. Howden, E. A. Grabsch, M. Graham, P. B. Ward, S. Xie, B. C. Mayall, P. D. R. Johnson, and M. L. Grayson. 2009. Prospective comparison of the clinical impact of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (hVISA) and vancomycinsusceptibile MRSA. Antimicrob. Agents Chemother. 53:3447-3452.
10. Howden, B. P., P. D. R. Johnson, P. B. Ward, T. P. Stinear, and J. K. Davies. 2006. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50:3039-3047.
11. Khosrovaneh, A., K. Riederer, S. Saeed, M. S. Tabriz, A. R. Shah, M. M. Hanna, M. Sharma, L. B. Johnson, M. G. Fakih, and R. Khatib. 2004. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 38:1328-1330.
12. Kim, M.-N., S. H. Hwang, Y.-J. Pyo, H.-M. Mun, and C. H. Pai. 2002. Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. J. Clin. Microbiol. 40:1376-1380.
13. Kosowska-Shick, K., L. M. Ednie, P. McGhee, K. Smith, C. D. Todd, A. Wehler, and P. C. Appelbaum. 2008. Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center. Antimicrob. Agents Chemother. 52: 4510-4513.
14. Leonard, S. N., K. L. Rossi, K. L. Newton, and M. J. Rybak. 2009. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J. Antimicrob. Chemother. 63:489-492.
15. Liu, C., and H. F. Chambers. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47: 3040-3045.
16. Maor, Y., M. Hagin, N. Belausov, N. Keller, D. Ben-David, and G. Rahav. 2009. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 199:619-624.
17. Maor, Y., G. Rahav, N. Belausov, D. Ben-David, G. Smollan, and N. Keller. 2007. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J. Clin. Microbiol. 45:1511-1514.
18. Mulvey, M. R., L. Chui, J. Ismail, L. Louie, C. Murphy, N. Chang, M. Alfa, and the Canadian Committee for the Standardization of Molecular Methods. 2001. Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis. J. Clin. Microbiol. 39:3481-3485.
19. Musta, A. C., K. Riederer, S. Shemes, P. Chase, J. Jose, L. B. Johnson, and R. Khatib. 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47:1640-1644.
20. Ofner-Agostini, M., M. Varia, L. Johnston, K. Green, A. Simor, B. Amihod, E. Bryce, E. Henderson, J. Stegenga, F. Bergeron, the Canadian Nosocomial Infection Surveillance Program, and D. Gravel. 2007. Infection control and antimicrobial restriction practices for antimicrobial-resistant organisms in Canadian tertiary care hospitals. Am. J. Infect. Control 35:563-568.
21. Oliveira, D. C., and H. de Lencastre. 2002. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 2155-2161.
22. Plipat, N., G. Livni, H. Bertram, and R. B. Thomson, Jr. 2005. Unstable vancomycin heteroresistance is common among clinical isolates of methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:2494-2496.
23. Rybak, M. J., S. N. Leonard, K. L. Rossi, C. M. Cheung, H. S. Sadar, and R. N. Jones. 2008. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 46:2950-2954.
24. Simor, A. E., M. Ofner-Agostini, E. Bryce, K. Green, A. McGeer, M. Mulvey, S. Paton, and the Canadian Nosocomial Infection Surveillance Program. 2001. The evolution of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 5 years of national surveillance. CMAJ 165:21-26.
25. Simor, A. E., M. Ofner-Agostini, E. Bryce, A. McGeer, S. Paton, M. R. Mulvey, and the Canadian Nosocomial Infection Surveillance Program. 2002. Laboratory characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: results of 5 years of national surveillance, 1995-1999. J. Infect. Dis. 186:652-660.
26. Steinkraus, G., R. White, and L. Friedrich. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycinsusceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794.
27. Van Griethuysen, A., A. Van 't Veen, A. Buiting, T. Walsh, and J. Kluytmans. 2003. High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands. J. Clin. Microbiol. 41:2487-2491.
28. Walsh, T. R., A. Bolmström, A. Qwärnström, P. Ho, M. Wootton, R. A. Howe, A. P. MacGowan, and D. Diekema. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.
29. Wang, G., J. F. Hindler, K. W. Ward, and D. A. Bruckner. 2006. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44:3883-3886.
30. Wootton, M., R. A. Howe, R. Hillman, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403.
31. Wootton, M., A. P. MacGowan, T. R. Walsh, and R. A. Howe. 2007. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 45:329-332.
32. Yusof, A., A. Engelhardt, Å. Karlsson, L. Bylund, P. Vidh, K. Mills, M. Wootton, and T. R. Walsh. 2008. Evaluation of a new Etest vancomycinteicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J. Clin. Microbiol. 46: 3042-3047.